Defymed is a spin -off of the “Centre Europeen d’etude du Diabete” (CeeD) which has been working on the conception of a bio-artificial pancreas since 1996.
This work was carried out in tight collaboration with the “Centre de Transfert de Technologie du Mans” (CTTM) and STATICE in the frame of two research European programs: FP4 (1996-2000) and FP6 (2004-2007). This work has led to the development of a prototype of MAILPAN® medical device.
Key dates of the project:
- 1996: Co-funding of the BARP project by the European commission under the 4th Framework Program (FP4). This project has been coordinated by the CeeD in tight collaboration with 10 European team
- 2004: Co-funding of the BARP+ project by the European commission under the 6th Framework Program (FP6) with a grant of 3 Million euros. This project has been coordinated by the CeeD in tight collaboration with 18 European teams and has led to the development of MAILPAN prototype
- December 2006: End of the BARP+ European project
- March 2007: BARP+ project recognized as one of the FP6 success stories
- November 2008: MAILPAN Project co-labeled by the Alsace Biovalley (Strasbourg) and Microtechnics (Besançon) competitivity poles
- April 2010: MAILPAN project incubated by the Alsace incubator SEMIA
- June 2010: MAILPAN project granted under the national innovation contest « Emergence » organized by the French research ministry and coordinated by Oseo
- June 2010: MAILPAN project granted by the region of Alsace
- March 2011: Foundation of Defymed
